Research Programme: Epigenetic reprogramming therapeutics - Life Biosciences
Latest Information Update: 19 Feb 2024
At a glance
- Originator Harvard University
- Developer Life Biosciences
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Eye disorders
Most Recent Events
- 19 Feb 2024 Life Biosciences plans to initiate IND enabling studies in 2025 (Life Biosciences pipeline, February 2024)
- 08 May 2023 Life Biosciences and Forge Biologics enters into manufacturing partnership for development of gene therapies
- 05 Apr 2023 Preclinical trials in Eye disorders in USA (Intravitreous) (Life Bioscience pipeline, April 2023)